Symbols / PXMD
PXMD Chart
About
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 50.51K |
| Enterprise Value | -394.34K | Income | -13.49M | Sales | — |
| Book/sh | -0.18 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | 0.00 | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.20 |
| Current Ratio | 0.36 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 2.44 | EPS next Y | -1.09 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-05-13 16:00 | ROA | -3.70% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 126.26M |
| Shs Float | — | Short Float | 8.62% | Short Ratio | 0.10 |
| Short Interest | — | 52W High | 0.02 | 52W Low | 0.00 |
| Beta | -39.60 | Avg Volume | 20.53K | Volume | 300.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-0.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-12-04 | init | HC Wainwright & Co. | — → Buy | $3 |
- PaxMedica announces board resignations amid transition - Investing.com Fri, 04 Apr 2025 07
- PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks Fri, 13 Jun 2025 07
- PXMD Stock Price and Chart — OTC:PXMD - TradingView Sat, 04 May 2024 14
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance Wed, 15 May 2024 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace Fri, 12 Apr 2024 07
- PaxMedica Announces 1-for-17 Reverse Stock Split - GlobeNewswire Mon, 30 Oct 2023 07
- PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq ue, 07 Nov 2023 08
- Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - Yahoo Finance Fri, 26 Aug 2022 07
- Why Is Motus GI (MOTS) Stock Down 37% Today? - InvestorPlace Fri, 12 Apr 2024 07
- Why Is Applied Digital (APLD) Stock Down 6% Today? - InvestorPlace Fri, 12 Apr 2024 07
- 7 Stocks With the Highest Short Interest This Week - InvestorPlace Mon, 27 Feb 2023 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -18.23M | -16.67M | -7.20M |
| TotalUnusualItems | -45.59K | 1.87M | -222.88K |
| TotalUnusualItemsExcludingGoodwill | -45.59K | 1.87M | -222.88K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.29M | -14.80M | -10.23M |
| EBITDA | -18.28M | -14.80M | -7.42M |
| EBIT | -18.28M | -14.80M | -7.42M |
| NetInterestIncome | -9.16K | -396.48K | -2.81M |
| InterestExpense | 9.16K | 5.24K | 2.81M |
| NormalizedIncome | -18.24M | -16.68M | -10.01M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.29M | -14.80M | -10.23M |
| TotalExpenses | 16.15M | 10.60M | 7.20M |
| TotalOperatingIncomeAsReported | -16.15M | -10.60M | -7.20M |
| DilutedAverageShares | 1.66M | 514.22K | 392.12K |
| BasicAverageShares | 1.66M | 514.22K | 392.12K |
| DilutedEPS | -11.00 | -28.79 | -26.01 |
| BasicEPS | -11.00 | -28.79 | -26.01 |
| DilutedNIAvailtoComStockholders | -18.29M | -14.80M | -10.23M |
| NetIncomeCommonStockholders | -18.29M | -14.80M | -10.23M |
| NetIncome | -18.29M | -14.80M | -10.23M |
| NetIncomeIncludingNoncontrollingInterests | -18.29M | -14.80M | -10.23M |
| NetIncomeContinuousOperations | -18.29M | -14.80M | -10.23M |
| PretaxIncome | -18.29M | -14.80M | -10.23M |
| OtherIncomeExpense | -2.14M | -3.80M | -225.31K |
| OtherNonOperatingIncomeExpenses | -2.09M | -5.68M | -2.43K |
| SpecialIncomeCharges | -45.59K | -161.56K | 59.89K |
| OtherSpecialCharges | 45.59K | 161.56K | -59.89K |
| GainOnSaleOfSecurity | 2.04M | -282.77K | |
| NetNonOperatingInterestIncomeExpense | -9.16K | -396.48K | -2.81M |
| TotalOtherFinanceCost | 391.25K | ||
| InterestExpenseNonOperating | 9.16K | 5.24K | 2.81M |
| OperatingIncome | -16.15M | -10.60M | -7.20M |
| OperatingExpense | 16.15M | 10.60M | 7.20M |
| ResearchAndDevelopment | 3.91M | 1.79M | 2.22M |
| SellingGeneralAndAdministration | 12.23M | 8.82M | 4.97M |
| GeneralAndAdministrativeExpense | 12.23M | 8.82M | 4.97M |
| OtherGandA | 12.23M | 8.82M | 4.97M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 7.40M | 707.98K | 589.20K |
| ShareIssued | 7.40M | 707.98K | 589.20K |
| TotalDebt | 173.54K | ||
| TangibleBookValue | 3.39M | 108.80K | -10.11M |
| InvestedCapital | 3.39M | 282.34K | -10.11M |
| WorkingCapital | 3.89M | 108.80K | -10.31M |
| NetTangibleAssets | 3.39M | 108.80K | -10.11M |
| CommonStockEquity | 3.39M | 108.80K | -10.11M |
| PreferredStockEquity | 5.00 | 5.00 | 270.00 |
| TotalCapitalization | 3.39M | 108.80K | -10.11M |
| TotalEquityGrossMinorityInterest | 3.39M | 108.80K | -10.11M |
| StockholdersEquity | 3.39M | 108.80K | -10.11M |
| RetainedEarnings | -52.03M | -33.74M | -18.94M |
| AdditionalPaidInCapital | 55.41M | 33.85M | 8.83M |
| CapitalStock | 745.00 | 76.00 | 961.00 |
| CommonStock | 740.00 | 71.00 | 691.00 |
| PreferredStock | 5.00 | 5.00 | 270.00 |
| TotalLiabilitiesNetMinorityInterest | 2.30M | 2.10M | 10.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 500.00K | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 500.00K | 0.00 | |
| NonCurrentDeferredRevenue | 500.00K | 0.00 | |
| CurrentLiabilities | 1.80M | 2.10M | 10.76M |
| OtherCurrentLiabilities | 160.95K | 9.34M | |
| CurrentDebtAndCapitalLeaseObligation | 173.54K | ||
| CurrentDebt | 173.54K | ||
| OtherCurrentBorrowings | 173.54K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 787.98K | 500.46K | 680.03K |
| PayablesAndAccruedExpenses | 1.01M | 1.26M | 1.42M |
| CurrentAccruedExpenses | 177.12K | 518.61K | 680.03K |
| InterestPayable | 0.00 | ||
| Payables | 830.23K | 741.96K | 737.00K |
| DuetoRelatedPartiesCurrent | 18.50K | 20.00K | 750.00 |
| AccountsPayable | 811.73K | 721.96K | 736.25K |
| TotalAssets | 5.68M | 2.20M | 648.87K |
| TotalNonCurrentAssets | 0.00 | 0.00 | 204.78K |
| NonCurrentDeferredAssets | 0.00 | 204.78K | |
| CurrentAssets | 5.68M | 2.20M | 444.09K |
| OtherCurrentAssets | 969.76K | 302.43K | |
| Receivables | 0.00 | 0.00 | |
| AccountsReceivable | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 4.71M | 1.90M | 444.09K |
| CashAndCashEquivalents | 4.71M | 1.90M | 444.09K |
| CashFinancial | 4.71M | 1.90M | 444.09K |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -10.77M | -6.07M | -5.51M |
| RepurchaseOfCapitalStock | -196.00K | -35.00K | |
| RepaymentOfDebt | -746.38K | 0.00 | |
| IssuanceOfDebt | 3.20M | 1.24M | 0.00 |
| IssuanceOfCapitalStock | 11.95M | 6.32M | 5.00M |
| EndCashPosition | 4.71M | 1.90M | 444.09K |
| BeginningCashPosition | 1.90M | 444.09K | 1.12M |
| ChangesInCash | 2.81M | 1.46M | -679.54K |
| FinancingCashFlow | 13.58M | 7.53M | 4.83M |
| CashFlowFromContinuingFinancingActivities | 13.58M | 7.53M | 4.83M |
| NetOtherFinancingCharges | -822.30K | -35.00K | -166.90K |
| NetPreferredStockIssuance | 0.00 | 300.00K | 0.00 |
| PreferredStockIssuance | 0.00 | 300.00K | 0.00 |
| NetCommonStockIssuance | 11.95M | 6.02M | 5.00M |
| CommonStockPayments | -196.00K | -35.00K | |
| CommonStockIssuance | 11.95M | 6.02M | 5.00M |
| NetIssuancePaymentsOfDebt | 2.45M | 1.24M | 0.00 |
| NetShortTermDebtIssuance | 2.45M | 1.24M | 0.00 |
| ShortTermDebtPayments | -746.38K | 0.00 | |
| ShortTermDebtIssuance | 3.20M | 1.24M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | ||
| LongTermDebtIssuance | 0.00 | ||
| OperatingCashFlow | -10.77M | -6.07M | -5.51M |
| CashFlowFromContinuingOperatingActivities | -10.77M | -6.07M | -5.51M |
| ChangeInWorkingCapital | 333.85K | 50.35K | 351.73K |
| ChangeInOtherWorkingCapital | 500.00K | ||
| ChangeInOtherCurrentAssets | 0.00 | -302.43K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 501.18K | 352.78K | 351.73K |
| ChangeInAccruedExpense | 46.46K | 238.62K | 101.50K |
| ChangeInInterestPayable | 0.00 | ||
| ChangeInPayable | 454.73K | 114.16K | 250.22K |
| ChangeInAccountPayable | 454.73K | 114.16K | 250.22K |
| ChangeInPrepaidAssets | -667.33K | 0.00 | |
| OtherNonCashItems | 91.99K | 525.75K | 2.81M |
| StockBasedCompensation | 5.20M | 4.42M | 1.34M |
| UnrealizedGainLossOnInvestmentSecurities | 1.82M | 109.18K | -175.78K |
| OperatingGainsLosses | 71.42K | 3.63M | 398.67K |
| GainLossOnInvestmentSecurities | 25.84K | 3.47M | 398.67K |
| NetIncomeFromContinuingOperations | -18.29M | -14.80M | -10.23M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PXMD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|